Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug
You may also be interested in...
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.
Pfizer, Roche, AstraZeneca: Emerging Markets Earnings Roundup (Part 3)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.